Skip to main content
Clinical Trials/NCT04041674
NCT04041674
Withdrawn
Phase 1

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants *Imatinib Mesylate Per Oral as a Clinical Therapeutic for TB

ConditionsHIV Infections

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
HIV Infections
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Primary Endpoint
Frequency of serious adverse events
Status
Withdrawn
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of a prime-boost vaccine regimen of GEO-D02 DNA and MVA/HIV62B with and without B63521^11 gp120 and IHV01 gp120 Env proteins in healthy, HIV-uninfected adult participants.

Detailed Description

This study will evaluate the safety and immunogenicity of a prime-boost vaccine regimen of GEO-D02 DNA and MVA/HIV62B with and without B63521\^11 gp120 and IHV01 gp120 Env proteins in healthy, HIV-uninfected adult participants. Participants will be randomly assigned to one of five groups. Participants in all five groups will receive GEO-D02 DNA by intramuscular (IM) injection at Months 0 and 2. Then, at Months 4, 6, and 10, participants will receive three additional injections according to their assigned group: * Group 1: MVA/HIV62B, placebo for B63521\^11 gp120, and placebo for IHV01, all by IM injection * Group 2: MVA/HIV62B by IM injection and placebo for B63521\^11 gp120 and for IHV01, both by subcutaneous (SC) injection * Group 3: MVA/HIV62B, B63521\^11 gp120, and IHV01, all by IM injection * Group 4: MVA/HIV62B, placebo for B63521\^11 gp120, and IHV01, all by IM injection * Group 5: MVA/HIV62B by IM injection and IHV01 and B63521\^11 gp120, both by SC injection Participants will attend several study visits through Month 16. Visits may include physical examinations, blood and urine collection, electrocardiogram, HIV testing, risk reduction counseling, and questionnaires. Study staff will contact participants at Month 24 for follow-up health monitoring.

Registry
clinicaltrials.gov
Start Date
March 1, 2022
End Date
May 31, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Frequency of serious adverse events

Time Frame: Measured through Month 16

Summarized using MedDRA System Organ Class and preferred terms

HIV-specific IgG binding breadth to cross-clade panels of gp120 and V1V2, and gp41

Time Frame: Measured through Month 10.5

As assessed by BAMA

Frequency of systemic reactogenicity signs and symptoms

Time Frame: Measured through Month 10

Systemic symptoms include increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, and nausea.

HIV-specific IgG binding magnitude to cross-clade panels of gp120 and V1V2, and gp41

Time Frame: Measured through Month 10.5

As assessed by binding antibody multiplex assay (BAMA)

Response rate of CD4+ T-cell responses to Env

Time Frame: Measured through Month 10.5

As assessed by intracellular cytokine staining (ICS)

HIV-specific IgG binding response rate to cross-clade panels of gp120 and V1V2, and gp41

Time Frame: Measured through Month 10.5

As assessed by BAMA

Magnitude of CD4+ T-cell responses to Env

Time Frame: Measured through Month 10.5

As assessed by ICS

Frequency of local reactogenicity signs and symptoms

Time Frame: Measured through Month 10

Local symptoms include pain and/or tenderness at the injection site.

Frequency of adverse events

Time Frame: Measured through Month 16

Summarized using Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and preferred terms

Secondary Outcomes

  • IgA responses to gp120 and gp41(Measured through Month 16)
  • IgG avidity to defined epitope specificities(Measured through Month 10.5)
  • HIV-specific IgG binding magnitude to gp120, V1V2, and gp41(Measured through Month 16)
  • Response rate of antibody-dependent cellular cytotoxicity (ADCC)-mediating antibody responses(Measured through Month 16)
  • IgA responses to gp120, V1V2, and gp41(Measured through Month 10.5)
  • IgG3 responses to gp120, V1V2, and gp41(Measured through Month 10.5)
  • HIV-specific IgG binding magnitude to V3, CD4i and gp41 IDR(Measured through Month 10.5)
  • HIV-specific IgG binding response rate to V3, CD4i and gp41 IDR(Measured through Month 10.5)
  • HIV-specific IgG binding response rate to gp120, V1V2, and gp41(Measured through Month 16)
  • Magnitude of antibody-dependent cellular phagocytosis (ADCP)-mediating antibody responses(Measured through Month 16)
  • IgG3 responses to gp120 and gp41(Measured through Month 16)
  • Magnitude of ADCC-mediating antibody responses(Measured through Month 16)
  • Response rate of vaccine-elicited antibody binding to FcƴR proteins(Measured through Month 16)
  • Magnitude of vaccine-elicited antibody binding to FcƴR proteins(Measured through Month 16)
  • Response rate of antibody-dependent cellular phagocytosis (ADCP)-mediating antibody responses(Measured through Month 16)

Similar Trials